Appeals Court Reaffirms DNA Patents; Myriad Case May Be Headed To Supreme Court
This article was originally published in The Gray Sheet
Executive Summary
A Federal Circuit panel again rules that Myriad Genetics’ patents covering BRCA genes isolated from the body are patent-eligible; the ACLU may request review by the full court or file a petition with the Supreme Court.